MedDRA preferred term · sudden reddening or warmth of the skin

Flushing: adverse event reports recording this term

100,508 reports to FDA record it, 2004–2026; 0.5% of the database.

Read first · FDA's statement on these data

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product. openFDA, FDA

FDA adds: "There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event." The information in these reports "cannot be used to estimate the incidence of these events."

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

100,508
reports recording the term: 0.5% of all reports; 3,986
reports, 12 months to June 2026: 4,005 in the 12 months before; 37.5%
marked serious by the reporter: 57.4% across all reports; 1.3%
record death among outcomes, as reported: 9.1% across all reports

100,508 reports in FDA's adverse event database record the MedDRA term "Flushing" (in plain words, sudden reddening or warmth of the skin): 0.5% of all reports received between January 2004 and June 2026. Coders pick the term that best matches the reporter's description.

3,986 reports recorded it in the 12 months to June 2026, close to the 4,005 of the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Of reports recording this term, 37.5% are marked serious, 1.3% include death among the outcomes and 13.3% include hospitalisation, as reported.

The drugs listed most often as suspect products in those reports are Niaspan, Tecfidera and Simcor. That order mostly follows how many reports each drug has overall; the table also gives the term's share within each drug's own reports. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

Reports by month, five years

FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

Drugs listed as suspect products in these reports

Drug	Class	Reports with this term	Share of the drug's own reports
Niaspan	—	17,053	53%
Tecfidera	—	16,542	14.5%
Simcor	—	4,978	48.3%
Remicade	Tumor necrosis factor blocker	1,787	1.2%
Vumerity	—	1,598	13.8%
Ampyra	Potassium channel blocker	1,579	2.8%
Paclitaxel	Microtubule inhibitor	1,510	2.2%
Orenitram	Prostacycline vasodilator	1,335	8%
Remodulin	Prostacycline vasodilator	1,223	2.6%
Copaxone	—	1,117	2.7%
Veletri	Prostacycline vasodilator	1,000	11.5%
Ambrisentan	Endothelin receptor antagonist	978	1.8%
Carboplatin	Platinum-based drug	919	0.9%
Dupixent	Interleukin-4 receptor alpha antagonist	866	0.2%
Tysabri	Integrin receptor antagonist	864	0.5%
Letairis	Endothelin receptor antagonist	861	1.7%
Uptravi	Prostacyclin receptor agonist	852	5%
Opsumit	Endothelin receptor antagonist	828	2%
Humira	—	808	0.1%
Oxaliplatin	Platinum-based drug	756	1.2%
Tyvaso	Prostacycline vasodilator	717	2.5%
Viagra	Phosphodiesterase 5 inhibitor	700	2.5%
Enbrel	Tumor necrosis factor blocker	631	0.1%
Infliximab	Tumor necrosis factor blocker	622	1.2%
Rituximab	CD20-directed cytolytic antibody	560	0.4%

Drugs with a page on this site, ordered by the number of their reports recording this term. The last column is the term's share within that drug's own reports, against 0.5% across the whole database. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

By pharmacologic class

Class	Reports with this term	Share of class reports	Median drug in class
Prostacycline vasodilator	4,879	4.1%	3.4%
Tumor necrosis factor blocker	3,958	0.4%	0.1%
Endothelin receptor antagonist	3,057	1.6%	1.4%
Phosphodiesterase 5 inhibitor	2,117	2.3%	2.3%
Microtubule inhibitor	2,029	1.4%	0.5%
CD20-directed cytolytic antibody	1,995	0.6%	0.7%
Platinum-based drug	1,778	0.8%	0.9%
Corticosteroid	1,774	0.2%	0.1%
Potassium channel blocker	1,705	2.6%	2.2%
Nonsteroidal anti-inflammatory drug	1,184	0.2%	0%

Classes ordered by count. Class shares follow the class's overall report volume as much as anything else.

Patients in these reports

Patient age

Under 20.3%283

2 to 111%961

12 to 171%1,055

18 to 4415.9%15,938

45 to 6423.2%23,314

65 to 748.2%8,241

75 and over4.3%4,282

Age not given46.2%46,434

Patient sex

Female58.7%59,025

Male35%35,157

Not given6.3%6,326

Grey bar: all 20,646,523 reports in the database. 79.9% of these reports give the United States as the country.

Questions about "Flushing"

What does "Flushing" mean in an adverse event report?

In plain language: sudden reddening or warmth of the skin. It is a MedDRA preferred term, the dictionary FDA uses to code what a reporter described. The report's own description is not published by openFDA and is not shown here.

How many reports record flushing?

100,508 reports through June 2026 (0.5% of all reports), 3,986 of them in the latest 12 months.

Which drugs appear most often in these reports?

Niaspan (17,053), Tecfidera (16,542), Simcor (4,978), Remicade (1,787) and Vumerity (1,598). Drugs with many reports overall lead almost every term's list. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Does a drug appearing here mean it was responsible for this reaction?

No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

I have this symptom. What should I do?

This site cannot assess anyone. A pharmacist or clinician can; for an emergency, call the local emergency number. Nothing on this page is medical advice.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. Terms are pooled across spelling and capitalisation variants of one MedDRA preferred term. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.

Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.